cytokine patterns after therapy with avonex®, rebif®, betaferon® and cinnovex® in relapsing–remitting multiple sclerosis in iranian patients
نویسندگان
چکیده
منابع مشابه
Cytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex™ in relapsing-remitting multiple sclerosis in Iranian patients.
AIM Several lines of evidence exist which suggest that changes in the expression of circulating cytokines are linked to the development or reoccurrence of multiple sclerosis (MS). This study aimed to evaluate the serum levels of relevant cytokines after therapy with IFN-β formulations in MS patients. MATERIALS & METHODS In this study, blood samples were collected from 70 MS patients undergoin...
متن کاملAntibodies to Interferon beta in Patients with Multiple Sclerosis Receiving CinnoVex, Rebif, and Betaferon
Treatment with interferon beta (IFN-β) induces the production of binding antibodies (BAbs) and neutralizing antibodies (NAbs) in patients with multiple sclerosis (MS). NAbs against IFN-β are associated with a loss of IFN-β bioactivity and decreased clinical efficacy of the drug. The objective of this study was to evaluate the incidence and the prevalence of binding antibodies (BAbs) and neutral...
متن کاملThe therapeutic effect of Avonex, Rebif and Betaferon on EDSS and relapse in multiple sclerosis: a comparative study.
We aimed to compare the therapeutic effect of Avonex (Av), Betaferon (Be) & Rebif (Re) on the Expanded Disability Status Scale (EDSS) in Multiple Sclerosis (MS). Ninety patients referring to Farshchian Hospital were entered in this study. The patients were divided into three equal groups: group 1 received Av, group 2 received Re and group 3 received Be, and after 24 months, comparison was done ...
متن کاملCost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran
BACKGROUND Disease-modifying drugs (DMDs) are a significant expenditure for treating multiple sclerosis (MS). However, there is limited report on assessment of the cost-utility of DMDs compared with symptom management in the presence of long-term data. This study aimed to assess the lifetime cost-utility from the Iranian healthcare perspectives of 4DMDs relative to symptom management alone in p...
متن کاملcomparison of the effects of cinnovex, rebif and betaferon on a expanded disability status scale of patients with multiple sclerosis
patients and methods in this study, a total of 92 patients with relapsing-remitting multiple sclerosis (rrms) were randomly allocated into three equal groups; each treatment group received one of the foregoing drugs (cinnovexr, rebif and betaferon) for one year. at the beginning and end of the study, patients ‘ edss was measured and compared. results in this study, the relative frequency of fem...
متن کاملthe therapeutic effect of avonex, rebif and betaferon on edss and relapse in multiple sclerosis: a comparative study
we aimed to compare the therapeutic effect of avonex (av), betaferon (be) & rebif (re) on the expanded disability status scale (edss) in multiple sclerosis (ms). ninety patients referring to farshchian hospital were entered in this study. the patients were divided into three equal groups: group 1 received av, group 2 received re and group 3 received be, and after 24 months, comparison was done ...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
research in pharmaceutical sciencesجلد ۷، شماره ۵، صفحات ۰-۰
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023